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Thirteen new hydroxyethylamines have been synthesized from reactions of (2S,3S)Boc-phenylalanine
epoxide, piperonylamine and arenesulfonyl chlorides in good yields. These compounds were evaluated as
antibacterial agents against Mycobacterium tuberculosis H37Rv using the Alamar Blue susceptibility test
and their activity expressed as the minimum inhibitory concentration (MIC) in mM. Two amino alcohols
displayed signiﬁcant activity when compared with ﬁrst line drug ethambutol (EMB). Therefore this class
of compounds could be a good starting point to develop new lead compounds in the treatment of
tuberculosis.
 2011 Elsevier Masson SAS. Open access under the Elsevier OA license.1. Introduction
Amino alcohols are very important and versatile compounds
with signiﬁcant applications in many ﬁelds, such as in synthetic
and medicinal chemistry. Different compounds containing the
moiety amino alcohols have been synthesized to use in various
diseases [1]. For example, compounds that present hydroxyethyl-
amines core have the capacity to inhibit aspartic protease enzymes
and are widely used as anti-HIV [2,3], antimalarial [4] and anti-
leishmaniose [5] agents. Recently, we reported the synthesis and
antimalarial activity against Plasmodium falciparum of hydrox-
yethypiperazines [6] and hydroxyethylsulfonamides derivatives [7].
The only amino alcohol used in the treatment of tuberculosis (TB)
disease is Ethambutol (EMB). Despite its modest anti-tuberculosis
activity, EMB is used in combination with other front-line anti-
tuberculosis agents mainly owing to its synergy with the other
drugs and also because it’s low toxicity [8].
Lee et al. [9] reported that the 1,2-ethylenediaminemoiety is the
EMB pharmacophore due the possibility of chelate formation with
divalent metal ions such copper, and that the best 1,2-diamine
synthesized was 35-fold more active than EMB. However, results
of advanced studies of this 1,2-ethylenediamine derivative forFármacos e Farmanguinhos,
co, 100, Manguinhos, 21041-
.
co).
nder the Elsevier OA license.treatment of tuberculosis show that it does not have the same
target as EMB [10]. It has also been reported that the presence of
a hydroxyl group b to the amine results in an increase in antitu-
bercular potency [8,9]. Moreover, the distance between oxygen
atom and nitrogen atom in EMB is the same distance of both atoms
in hydroxyethylamine structure suggesting good relationship
between both structures (Fig. 1).
Tuberculosis (TB) is a chronic bacterial infection transmitted
through the air. This disease is caused by the bacteria Mycobacte-
rium tuberculosis and mainly affects the lungs (pulmonary TB),
which is responsible for more than 75 percent of cases, but it may
also affect different parts of the body, such as the brain, stomach,
bones, skin, intestine, liver, kidneys, spinal cord and breasts [11,12].
Different factors are responsible for the resurgence of TB, such the
AIDS epidemic, which emerged in the mid-1980s and immigration,
war, famine, homelessness.
A serious problemworldwide in the ﬁght against TB is the rapid
spread of the multidrug-resistant (MDR) TB due to inconsistent or
partial treatment, and the lack of new drugs in the market.
Particularly worrisome is the super bacterium XDR-TB (extensively
drug-resistant tuberculosis), which is resistant to all ﬁrst and
second line anti-TB drugs. Because of these problems, the World
Health Organization (WHO) declared TB a global health emergency
in 1993. According to statistical data, 9.27 million people world-
wide develop active TB and almost 1.77 million die every year [13].
To overcome the problemswith available treatments, new drugs
to treat TB are urgently required, speciﬁcallymore potent therapies,
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Fig. 1. Ethambutol and hydroxyethylamine-based structures.
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Scheme 1. Reaction and conditions: i: IPA, reﬂux, 16 h; ii: TFA/CH2Cl2 (1/3), r.t., 4 h; iii: Et3N, DMF, ArSO2Cl, CH2Cl2, r.t., 4 h; iv: H2, Pd/C 10%, EtOH, r.t., 16 h.
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and to be employed to treat MDR TB and latent disease. In this
context and in the course of our investigations on hydroxyethyl-
amine derivatives [6,7], the aim of this work is the synthesis and in
vitro activity of novel hydroxyethylsulfonamide-based compounds,
against M. tuberculosis.Table 1
Yields and selected physical properties of compounds 3, 4, 5aef and 6aee.
Product R m.p.a (C) Yieldb (%) LC/MS m/z (%)
3 e 148e149 92 415.2 (Mþ þ 1, 100)
4 e oil 95 315.2 (Mþ þ 1, 100)2. Results and discussion
2.1. Chemistry
The target compounds 3, 4, 5aef and 6aee were prepared as
outlined in Scheme 1 and Scheme 2. The selective ring-opening of
the (2S,3S)Boc-phenylalanine epoxide 1 with piperonilamine 2 in
reﬂux of isopropanol afforded the hydroxyethylamine intermediate
3, which was coupled with arenesulfonyl chlorides by using trie-
thylamine, CH2Cl2 and DMF (catalytic concentration) at room
temperature to give the hydroxyethylsulfonamides 5aee in good
yields (Scheme 1). The compound 5f was prepared by reduction
reaction of nitro group of compound 5e with H2 Pd/C 10% using
ethanol in quantitative yield. We also synthesized the amino
alcohol 4 after deprotection of tert-butoxycarbonil group with tri-
ﬂuoroacetic acid and CH2Cl2 (1/3) mixture at room temperature in
quantitative yield (Scheme 1).
The amino alcohols 6aeewere prepared in excellent yields from
reaction of hydroxyethylsulfonamides 5aee with a solution of tri-
ﬂuoroacetic acid andmethylene chloride (1/3) at room temperatureNH
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Scheme 2. Reaction and conditions: i: TFA/CH2Cl2 (1/3), r.t., 4 h.for 4 h without any puriﬁcation as an oil (Scheme 2). Table 1 shows
the yields, melting points and LCeMSdata for compounds 3, 4, 5aef
and 6aee.
All the compounds were identiﬁed by 1H, 13C NMR and by
LCeMS data. In the proton nuclear magnetic resonance spectra (1H
NMR), the signals of hydrogen for the synthesized compoundswere
veriﬁed on the basis of their chemical shifts, multiplicities and
coupling constants (Table 2). 2D-NMR techniques (HMBQ, HMQCand COSY) helped us to assign the correct signals of compounds. For
the hydroxyethylamine core, the protons H1 appears as two
double-doublets more shielded than the protons H4, which also
shows two double-doublets. The two multiplets in the 1H NMR
spectra in the range of d 3.59 to 3.37 ppm were assigned to the H2
and H3 protons. The 13C NMR spectra exhibited CH signals at
d 72e71 ppm for C3 (CeOH) and at d 56e60 ppm for C2 (CeNH).
The CH2 signals for C4 and C1 appears at d 49e55 ppm and
35e38 ppm, respectively.2.2. Anti-mycobacterial activity
The results of anti-mycobacterial activity of all compounds 3, 4,
5aef and 6aee is shown in Table 3. The intermediates 3 and 4
showed poor activity suggesting that the sulfonamide moiety was
important to activity. Clearly, the presence of amino alcohol moiety
on hydroxyethylsulfonamides 6aee is crucial for anti-mycobacte-
rial activity since the presence of the carbamate moiety (tert-
butoxycarbonyl group) leads to loss of activity (5aef). This infor-
mation was in according with literature reported once reduced5a Br 189e190 93 673.0 (Mþ þ K, 100)
5b OMe 160e161 71 623.2 (Mþ þ K, 51)
5c Me 175e177 89 607.1 (Mþ þ K, 100)
5d F 159e161 72 611.2 (Mþ þ K, 100)
5e NO2 194e195 76 638.2 (Mþ þ K, 94)
5f NH2 oil 91 535.2 (Mþ þ 1, 100)
6a Br oil 79 532.1 (Mþ þ 1, 98)
6b OMe oil 66 484.2 (Mþ þ 1, 100)
6c Me oil 68 473.1 (Mþ þ 1, 100)
6d F oil 68 500.1 (Mþ þ 1, 100)
6e NO2 oil 61 415.2 (Mþ þ 1, 100)
a melting points are uncorrected.
b yields of puriﬁed compounds.
Table 2
Selected 1H and 13C NMR data of compounds 3, 4, 5aef and 6aee.
d (ppm) for 1H NMR (JH-H Hz) and 13C NMR (JC-F Hz)a
3 7.27e7.19 (m; 2H); 7.17e7.15 (m; 3H); 6.92 (s; 1H); 6.83 (d; 1H; J ¼ 7.9); 6.75 (d; 1H; J ¼ 7.8); 6,66 (d; 1H; J ¼ 9.1; OH); 5.96 (s; 2H; OCH2O); 4.79 (br; 1H; NH);
3.59 (s; 2H; H5); 3.59e3.56 (m; 1H; H2); 3.45e3.44 (m; 1H; H3); 2.97 (dd; 1H; J ¼ 13.8; 2J ¼ 3.1H4a); 2.55 (dd; 1H; J ¼ 13.6; 2J ¼ 3.5; H4b); 2.49 (dd; J ¼ 11.9; 2J
¼ 6.5; H1a); 2.44 (dd; 1H; J ¼ 11.9; 2J ¼ 7.4; H1b); 1.24 (s; 9H; C(CH3)3).
155.3 (C]O); 147.2, 145.8, 139.8, 134.9, 129.1, 127.9, 125.6, 121.0, 108.4, 107.8 (aryl); 100.6 (OCH2O); 77.3 (C(CH3)3); 72.0 (C3); 55.1 (C2); 52.8 (C5); 51.6
(C4); 36.1
(C1); 28.2 (C(CH3)3).
4 7.19e6.55 (m; 5H); 6.92 (s; 1H); 6.83 (d; 1H; J ¼ 7.9); 6.75 (d; 1H; J ¼ 7.8); 6.66 (d; 1H; J ¼ 9.1; OH); 5.96 (s; 2H; OCH2O); 4.79 (br; 1H; NH); 3.59 (s; 2H; H5);
3.59e3.55 (m; 1H; H2); 3.44e3.43 (m; 1H; H3); 2.97 (dd; 1H; J ¼ 13.8; 2J ¼ 3.1H4a); 2.55 (dd; 1H; J ¼ 13.6; 2J ¼ 3.5; H4b); 2.49 (dd; J ¼ 11.9; 2J ¼ 6.5; H1a);
2.44 (dd; 1H; J ¼ 11.9; 2J ¼ 7.4; H1a).
147.2, 145.8, 139.8, 134.9, 129.7, 129.2, 127.5, 121.0, 108.4, 107.8 (aryl); 100.6 (OCH2O); 72.0 (C3); 55.1 (C2); 52.8 (C5); 51.6 (C4); 36.1 (C1).
5a 7.80e7.76 (m; 2H); 7.74e7.73 (m; 2H); 7.23e7.18 (m; 2H); 7.16e7.11 (m; 3H); 6.83 (d; 1H; J ¼ 8.4); 6.77 (s; 1H) 6.76 (d; 1H; J ¼ 7.1); 6.62 (d; 1H; J ¼ 9.0; OH);
5.99 (d; 2H; J ¼ 2.7; OCH2O); 4.99 (d; 1H; J ¼ 6.5; NH); 4.45 (d; 1H; J ¼ 15.4; H5a); 4.29 (d; 1 H; J ¼ 15.4; H5b); 3.50e3.42 (m; 2H; H2, H3); 3.01 (dd; 1H; J
¼ 14.7; 2J
¼ 8.6; H4a); 2.90 (dd; 1H; J ¼ 13.8; 2J ¼ 2.8; H4b); 2.51e2.48 (m; 1H; H1a); 2.44 (dd; 1H; J ¼ 13.6; 2J ¼ 10.8; H1b); 1.21 (s; 9H; C(CH3)3).
155.2 (C]O); 147.2, 146.6, 139.6, 139.4, 132.1, 130.1, 129.1, 129.1, 128.9, 127.8, 126.4, 125.6, 121.8, 108.4, 107.9 (aryl); 100.9 (OCH2O); 77.4 (C(CH3)3); 71.5 (C3);
54.9 (C2); 50.9 (C5); 50.2 (C4); 35.3 (C1); 28.1 (C(CH3)3).
5b 7.76 (d; 2H; J ¼ 8.8); 7.22 (t; 2H; J ¼ 7.4); 7.17e7.13 (m; 3H); 7.09 (d; 2H; J ¼ 8.8); 6.81 (d; 1H; J ¼ 7.8); 6.76 (s; 1H); 6.75 (d; 1H; J ¼ 7.9); 6.71 (d; 1H; J ¼ 8.8;
OH); 5.97 (d; 2H; J ¼ 2.4; OCH2O); 4.92 (d; 1H; J ¼ 6.1; NH); 4.38 (d; 1H; J ¼ 15.5; H5a); 4.26 (d; 1H; J ¼ 15.4; H5b); 3.84 (s; 3H; OMe); 3.53e3.46 (m; 2H;
H2, H3); 3.35e3.30 (m; 1H; H4a); 2.95e2.89 (m; 2H; H4b, H1a); 2.46 (dd; 1H; J ¼ 13.5; 2J ¼ 10.6; H1b); 1.23 (s; 9H; C(CH3)3).
162.3 (aryl); 155.2 (C]O); 147.2, 146.4, 139.5, 131.6, 130.5, 129.2, 129.1, 127.8, 125.6, 121.7, 114.3, 108.5, 107.9 (aryl); 100.9 (OCH2O); 77.4 (C(CH3)3); 71.9 (C3);
55.6 (OCH3); 54.8 (C2); 51.2 (C5); 50.4 (C4); 35.1 (C1); 28.1 (C(CH3)3).
5c 7.70 (d; 2H; J ¼ 8.1); 7.38 (d; 2H; J ¼ 8.0); 7.25e7.20 (m; 2H); 7.15e7.12 (m; 3H); 6.81 (d; 1H; J ¼ 8.4); 6.75 (s; 1H); 6.74 (d; 1H; J ¼ 7.8); 6.59 (d; 1H; J
¼ 9.0; OH); 5.97 (d; 2H; J ¼ 2.3; OCH2O); 4.94 (d; 1H; J ¼ 6.3; NH); 4.39 (d; 1H; J ¼ 15.4; H5a); 4.27 (d; 1H; J ¼ 15.4; H5b); 3.51e3.42 (m; 2H; H2, H3); 3.35e3.31
(m; 1H; H4a); 2.96e2.87 (m; 2H; H4b, H1a); 2.46 (dd; 1H; J ¼ 13.8; 2J ¼ 10.5; H1b); 2.40 (s; 3H; CH3); 1.22 (s; 9H; C(CH3)3).
155.2 (C]O); 147.3, 146.5, 143.0, 139.5, 137.1, 130.5, 129.7, 129.2, 127.9, 127.0, 125.7, 121.8, 108.5, 108.0 (aryl); 100.9 (OCH2O); 77.5 (C(CH3)3); 71.9 (C3); 54.9
(C2); 51.2 (C5); 50.5 (C4); 35.1 (C1); 28.1 (C(CH3)3); 21.0 (CH3).
5d 7.89 (dd; 2H; J ¼ 8.7; 2J ¼ 5.2); 7.41 (t; 2H; J ¼ 8.8); 7.23e7.20 (m; 2H); 7.16e7.11 (m; 3H); 6.82 (d; 1H; J ¼ 4.0); 6.76 (s; 1H); 6.75 (d; 1H; J ¼ 7.4); 6.62 (d; 1H;
J ¼ 8.9; OH); 5.98 (d; 2H; J ¼ 2.4; OCH2O); 4.99 (d; 1H; J ¼ 6.4; NH); 4.44 (d; 1H; J ¼ 15.4; H5a); 4.29 (d; 1H; J ¼ 15.4; H5b); 3.55e3.43 (m; 2H; H2 and H3); 2.99
(dd; 1H; J ¼ 14.8; 2J ¼ 8.7; H1a); 2.90 (d; 1H; J ¼ 13.5; J ¼ ¼ 3.0; H4a); 2.49e2.47 (m; 1H; H4b); 2.42 (dd; 1H; J ¼ 14.8; 2J ¼ 9.8; H1b); 1.21 (s; 9H; C(CH3)3).
164.2 (d; J ¼ 250.0; aryl)); 155.2 (C]O); 147.3; 146.6; 139.5; 136.7; 130.2; 130.0 (d; 3JCF ¼ 9.0); 129.2; 127.9; 125.7; 121.8; 116.3 (d; 2J ¼ 22.3); 108.5; 108.0
(aryl); 101.0 (OCH2O); 77.5 (C(CH3)3); 71.6 (C3); 54.9 (C2); 50.9 (C5); 50.2 (C4); 35.3 (C1); 28.1 (C(CH3)3).
5e 8.37 (d; 2H; J ¼ 8.8); 8.08 (d; 2H; J ¼ 8.8); 7.23e7.21 (m; 2H); 7.15e7.11 (m; 3H); 6.85 (d; 1H; J ¼ 7.9); 6.79 (s; 1H); 6.78 (d; 1H; J ¼ 7.9); 6.62 (d; 1H;
J ¼ 9.0; OH); 5.99 (d; 2H; J ¼ 3.3; OCH2O); 4.99 (d; 1H; J ¼ 6.6; NH); 4.56 (d; 1H; J ¼ 15.3; H5a); 4.33 (d; 1H; J ¼ 15.4; H5b); 3.52e3.38 (m; 2H; H2, H3); 3.11
(dd; 1H; J ¼ 14.8; 2J ¼ 8.8; H4a); 2.90 (dd; 1H; J ¼ 13.2; 2J ¼ 3.2; H4b); 2.50e2.48 (m; 1H; H1a); 2.43 (dd; 1H; J ¼ 13,7; 2J ¼ 10.8; H1b); 1.21 (s; 9H; C(CH3)3).
155.2 (C]O); 149.5, 147.4, 146.7, 146.1, 139.4, 129.8, 129.8, 129.3, 129.1, 128.6, 127.9, 125.7, 124.4, 121.9, 108.5, 108.1 (aryl); 101.1 (OCH2O); 77.5 (C(CH3)3);
71.2 (C3); 54.9 (C2); 50.7 (C5); 50.1 (C4); 35.4 (C1); 28.1 (C(CH3)3).
5f 7.44 (d; 2H; J ¼ 8.6); 7.23e7.18 (m; 2H); 7.16e7.13 (m; 3H); 6.80 (d; 1H; J ¼ 7.7); 6.75 (s; 1H); 6.74 (d; 1H; J ¼ 8.0). 6.61 (d; 2H); 6.55 (d; 1H; J ¼ 9.0; OH); 5.99
(s; 2 H; NH2); 5.97 (d; 2H; J ¼ 2.4; OCH2O); 4.83 (d; 1H; J ¼ 6.0; NH); 4.29 (d; 1H; J ¼ 15. 4; H5a); 4.18 (d; 1H; J ¼ 15.3; H5b); 3.57e3.44 (m; 2H; H2, H3); 3.30
(dd; 1H; J ¼ 14.6; 2J ¼ 3.2; H4a); 2.90 (dd; 1H; J ¼ 13.8; 2J ¼ 2.6; H4b); 2.80 (dd; 1H; J ¼ 14.4; 2J ¼ 8.0; H1a); 2.47e2.45 (m; 1H; H1b); 1.23 (s; 9H; (C(CH3)3);
1.10 (s; 2H; NH2).
155.1 (C]O); 152.7, 147.1, 146.2, 139.5, 130.9, 129.0, 128.8, 127.7, 124.3, 121.5, 112.6, 112.6, 108.4, 107.7 (aryl); 100.7 (OCH2O); 77.3 (C(CH3)3); 72.1 (C3); 54.7
(C2); 51.4 (C5); 50.5 (C4); 34.9 (C1); 28.0 (C(CH3)3).
6a 7.77 (d; 2H; J ¼ 8.7); 7.73 (d; 2H; J ¼ 8.7); 7.28e7.23 (m; 2H); 7.19e7.16 (m; 3H); 6.85 (d; 1H; J ¼ 7.4); 6.78 (s; 1H); 6.75 (d; 1H; J ¼ 8.0); 5.99 (s; 2H;
OCH2O); 4.75 (d; 1H; J ¼ 5.7; NH); 4.41 (d; 1H; J ¼ 15.5; H5a); 4.34 (d; 1H; J ¼ 15.4; H5b); 3,45 (dd; 1H; J ¼ 14.5; 2J ¼ 2.4; H4a); 3.42e3.37 (m; 1H; H2); 3.12
(dd; 1H; J ¼ 14.8; 2J ¼ 8.7: H1a); 2.71 (dd; 1H; J ¼ 14.4; 2J ¼ 3.0; H4b); 2.30 (dd; 1H; J ¼ 14.7; 2J ¼ 9.8; H1b); 1.27 (br; 2H; NH2).
147.2, 146.5, 139.8, 139.5, 132.2, 130.4, 129.2, 128.9, 128.1, 126.3, 125.8, 121.7, 108.4, 107.9 (aryl); 100.9 (OCH2O); 72.2 (C3); 56.1 (C2); 51.4 (C5); 49.9
(C4); 36.7 (C1).
6b 7.76 (d; 2H; J ¼ 8.9); 7.27e7.24 (m; 2H); 7.20e7.14 (m; 3H); 7.09 (d; 2H; J ¼ 8.9); 6.83 (d; 1H; J ¼ 7.9); 6.74 (d; 1H; J ¼ 7.9); 5.98 (s; 2H; OCH2O); 4.70
(d; 1H; J ¼ 5.6; NH); 4.32 (s; 2H; H5); 3.85 (s; 3H; OCH3); 3.44e3.40 (m; 2H; H2, H3); 3.04 (dd; 1H; J ¼ 13.9; 2J ¼ 8.0, H4a); 2.74e2.70 (m; 2H; H4b, H1a);
2.29 (dd; 1H; J ¼ 14.1; 2J ¼ 9.6, H1b); 1.17 (br; 2H; NH2).
162.3, 147.2, 146.4, 139.9, 131.5, 130.8, 129.2, 129.1, 128.0, 125.7, 121.6, 114.3, 108.4, 107.9 (aryl); 100.9 (OCH2O); 72.5 (C3); 56.0 (OCH3); 55.6 (C2); 51.6 (C5);
50.2 (C4); 36.3 (C1).
6c 7.70 (d; 2H; J ¼ 8.2); 7.39 (d; 2H; J ¼ 8.0); 7.27e7.24 (m; 2H); 7.20e7.17 (m; 2H); 6.75 (d; 1H; J ¼ 7.9); 6.73 (s; 1H); 6.72 (dd; 1H; J ¼ 6.9; 2J ¼ 1.2); 5.98
(s; 2H; OCH2O); 4.78 (br; 1H; NH); 4.32 (s; 2H; H5); 3.46e3.41 (m; 2H; H2, H3); 3.04 (dd; 1H; J ¼ 15.1; 2J ¼ 9.0; H4a); 2.79e2.76 (m; H4b, H1a); 2.40 (s; 3H;
CH3); 2.32 (dd; 1H; J ¼ 14.3; 2J ¼ 8.6; H1b); 1.24 (br; 2H; NH2).
147.4, 146.7, 143.3, 139.9, 137.1, 131.0, 129.9, 129.4, 128.4, 127.2, 126.1, 121.9, 108.7, 108.1 (aryl); 101.1 (OCH2O); 72.5 (C3); 56.1 (C2); 51.9 (C5); 50.4 (C4);
38.7 (C1); 21.2 (CH3).
6d 7.90e7.86 (m; 2H); 7.40 (t; 2H; J ¼ 8.8); 7.27e7.22 (m; 2H); 7.19e7.14 (m; 3H); 6.83 (d; 1H; J ¼ 7.9); 6.77 (s; 1H); 6.74 (d; 1H; J ¼ 8.0); 5.99 (s; 2H;
OCH2O); 4.74 (d; 1H; J ¼ 5.2; NH); 4.40 (d; 1H; J ¼ 15.5; H5a); 4.35 (d; 1H; J ¼ 15.4; H5b); 3.45 (dd; 1H; J ¼ 14.5; 2J ¼ 2.7; H4a); 3.41e1.32
(m; 2H; H2, H3); 3.11 (d; 1H; J ¼ 14.5; 2J ¼ 8.6; H4b); 2.76e2.69 (m, 1H; H1a); 2.30 (dd; 1H; J ¼ 14.2; 2J ¼ 10.0; H1b); 1.28 (br; 2H; NH2).
164.2 (d; J ¼ 249.0), 147.2, 146.6, 139.8, 136.6, 130.5, 130.0 (d; 3J ¼ 9.1), 129.2, 128.1, 125.7, 121.6, 116.2 (d; 2J ¼ 22.2), 108.4, 107.9 (aryl); 100.9 (OCH2O); 72.3
(C3); 56.1 (C2); 51.3 (C5); 49.9 (C4); 35.3 (C1)
6e 8.35 (d; 2H; J ¼ 8.8); 8.06 (d; 2H; J ¼ 8.8); 7.26e7.23 (m; 2H); 7.17e7.14 (m; 3H); 6.85 (d; 1H; J ¼ 7.8); 6.81 (d; 1H; J ¼ 1.3); 6.77 (dd; 1H; J ¼ 6.0; 2J ¼ 1.3); 5.99
(d; 2H; J ¼ 2.5; OCH2O); 4.76 (d; 1H; J ¼ 5.3; NH); 4.5 (d; 1H; J ¼ 15.4; H5a); 4.39 (d; 1H; J ¼ 15.4; H5b); 3.49 (dd; 1H; J ¼ 14.4; 2J ¼ 1.9; H4a); 3.22 (dd; 1H;
J ¼ 14.5; 2J ¼ 9.0; H4b); 2.75e2.67 (m; 3H; H2, H3, H1a); 2.30 (dd; J ¼ 14.4; 2J ¼ 10.3; H1b); 1.27 (br; 2H; NH2).
149.4, 147.3, 146.6, 146.0, 139.7, 130.1, 129.2, 128.5, 128.1, 125.8, 124.3, 121.7, 108.4, 108.0 (aryl); 101.0 (OCH2O); 71.9 (C3); 56.1 (C2); 51.2 (C5); 49.7 (C4);
38.8 (C1).
a NMR Spectra in DMSO-d6/TMS.
W. Cunico et al. / European Journal of Medicinal Chemistry 46 (2011) 974e978976basicity of amino group results in a loss of activity. [9] The amino
alcohol moiety on hydroxyethylsulfonamides 6aee is more closely
to ethambutol structure than carbamate moiety of hydrox-
yethylsulfonamides 5aee. The best results were obtained for aminoalcohols 6a, 6b and 6c, especially for amino alcohol 6a (R ¼ Br) that
exhibit the highest activity (MIC ¼ 23.5 mM). The compound with
the strongly electron withdrawing nitro (6e) did not show activity,
suggesting that the substituent in the phenyl ring is important for
Table 3
The in vitro activity of compounds 3, 4, 5aef and 6aee against Mycobacterium
tuberculosis H37Rv strain (ATCC 27294, susceptible to ethambutol).
Comp. R MIC (mM) logP
3 e 241 5.152
4 e 318 1.409
5a Br >500 7.114
5b OMe >500 6.362
5c Me >500 6.754
5d F >500 5.381
5e NO2 >500 6.264
5f NH2 >500 6.469
6a Br 23.5 3.371
6b OMe 51.6 2.619
6c Me 106 3.010
6d F 211 1.638
6e NO2 >500 2.521
EMB e 15.9 0.35
W. Cunico et al. / European Journal of Medicinal Chemistry 46 (2011) 974e978 977the biological activity. Three other compounds (3, 4, and 6d)
exhibited low activity (MIC up to 200 mM). The more active
compounds are at least 1.5e6 times less active than EMB
(MIC ¼ 15.9 mM), their IC50 values are in the micromolar concen-
tration range comparable to recently reported results [10] and
could be a start point to ﬁnd new compounds with better antitu-
bercular activity. Lipophilicities of the compounds 3, 4, 5aef, 6aee
and the standard drug EMB, which were expressed as logP values,
were determined using logP method through online http://www.
molinspiration.com/cgi-bin/properties site, as show in Table 3.
3. Experimental
3.1. Materials and methods
Unless otherwise indicated, common reagents and solvents
were used as obtained from commercial suppliers without further
puriﬁcation. All melting points were determined on a Buchi
Melting Point B-545 and are uncorrected. 1H and 13C NMR spectra
were recorded using a Bruker DRX 400 spectrometer (1H at
400.14 MHz and 13C at 100.61 MHz) or with a Bruker Avance 500
spectrometer (1H at 500.13 MHz and 13C at 125.75 MHz) in DMSO-
d6 containing TMS as in internal standard. The low resolution LC/
MS analyses were performed on an LC/MS micromass ZMD using
chloroform/methanol 1:1 as mobile phase with ﬂux of 0.3 mL/min.
The analyses used Electrospray Ionization technique on positive ion
mode. Samples were introduced by the standard direct insertion
probe method.
3.2. General procedure for the preparation of compound 3
Epoxide 1 (1.6 mmol) and piperonylamine 2 (1.5 mmol) were
dissolved in isopropanol (10 mL) and stirred under reﬂux for 16 h.
After this period, the solvent was removed by evaporation and the
crude product was puriﬁed by crystallization in methanol/water
(7:3).
3.3. General procedure for the preparation of compounds 5aee
The compound 3 was dissolved in CH2Cl2 (10 mL) and then TEA
(2.2 mmol) and DMF (0.2 mmol) were added. The mixture was
stirred for 30 min over nitrogenous atmosphere, arenesulfonyl
chloride (2.0 mmol) was added portion wise and stirred over 8 h.
The organic layer was washed with 5% HCl aqueous solution, water,
brine and dried over MgSO4. The solvent was removed in high
vacuum and the products 5aeewere obtained after recrystalization
in hot hexane.3.4. General procedure for the preparation of compound 5f
To a stirred solution of nitro compound 5e (0.57 mmol) in
absolute ethanol (15 mL) under a blanket of nitrogen was added
10% palladium on activated charcoal (5 mg). The reaction was
evacuated, placed under a hydrogen atmosphere and stirred over-
night. The reaction mixture was ﬁltered through Celite and the
solvent was removed under reduced pressure to yield brown oil.
The residue was puriﬁed by chromatography on silica, eluting with
3:1 hexane/ethyl acetate.3.5. General procedure for the preparation of compounds 4 and
6aee
Triﬂuoracetic acid (1.5 mL, 20 mmol) was added to a solution of
the compounds 3 or 5aee (2 mmol) in CH2Cl2 (6 mL). After 4 h at
room temperature, the solvent was removed in high vacuum. The
residue was dissolved in EtOAc (20 mL), washed with 5% NaHCO3
aqueous solution, H2O, brine and dried over MgSO4. The solvent
was removed to afford the compounds 4 or 6aee, respectively,
without any further puriﬁcation.3.6. Anti-mycobacterial activity
The anti-mycobacterial activities of compounds 3, 4, 5aef and
6aee have been assessed against M. tuberculosis ATTC 27294 using
the micro plate Alamar Blue assay (MABA) [14] (Table 3). This
methodology is nontoxic, uses a thermally-stable reagent and
shows good correlation with proportional and BACTEC radiometric
methods [15,16]. The method is described as follows: 200 ml of
sterile deionizedwater was added to all outer-perimeter wells of 96
sterile well plates (falcon, 3072: Becton Dickinson, Lincoln Park, NJ)
to minimize evaporation of the medium in the test wells during
incubation. The 96 plates received 100 mL of the Middlebrook 7H9
broth (Difco laboratories, Detroit, MI, USA) and successive dilution
of the compounds was made directly on the plate. The ﬁnal drug
concentrations tested were 0.01e20.0 mg/mL. Plates were covered
and sealed with paraﬁlm and incubated at 37  C for ﬁve days.
25 mL of a freshly prepared 1:1 mixture of Alamar Blue (Accumed
International, WestlakeOhio) reagent and 10% tween 80 was then
added to the plate and incubated for 24 h. A blue color in the well
was interpreted as no bacterial growth, and a pink color was scored
as growth. The minimal inhibition concentration (MIC) was deﬁned
as the lowest drug concentration, which prevented a color change
from blue to pink.4. Conclusion
In conclusion, the synthesis of thirteen hydroxyethylamines
derivatives 3, 4, 5aef and 6aee were easily performed with good
yields. All compounds were tested againstM. tuberculosis and three
of them (6aec) exhibit signiﬁcant activity when compared with
ﬁrst line drug ethambutol (EMB) with amino alcohol 6a (R ¼ Br)
showing the best activity (MIC ¼ 23.5 mM). It suggests that these
amino alcohols could be a good start point to ﬁnd new lead
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